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The association of mycosis fungoides and a primary
cutaneous CD30z lymphoproliferative disorder has been
reported and probably represents different clinical aspects
of a unique T-cell monoclonal expansion. In this study,
12 patients (6 men and 6 women) presented with
lymphomatoid papulosis and mycosis fungoides. A
TCRc gene rearrangement study was performed by an
automated high-resolution PCR fragment analysis
method on skin biopsy specimens taken from the different
clinical lesions in each patient. An indolent clinical course
was observed in the majority of patients. T-cell clonality
was identified in 7 of 12 lymphomatoid papulosis lesions
(58%) and in 6 skin biopsies of plaque stage mycosis
fungoides (50%). In each individual case, where T-cell
clonality was detected, both mycosis fungoides and
lymphomatoid papulosis specimens exhibited an identical
peak pattern by automated high-resolution PCR frag-
ment analysis, confirming a common clonal origin. Only
one case showed a clonal TCRc rearrangement from the
lymphomatoid papulosis lesion, which could not be
demonstrated in the mycosis fungoides specimen. The
demonstration of an identical clone seems to confirm that
both disorders are different clinical manifestations of a
unique T-cell monoclonal proliferation. Our results also
seem to confirm that the association of mycosis fungoides
with a primary cutaneous CD30z lymphoproliferative
disorder usually carries a favourable prognosis. Key
words: mycosis fungoides; lymphomatoid papulosis; T-
cell clonality; PCR; Genescan.
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The simultaneous observation of a CD30z cutaneous
lymphoproliferative disorder (lymphomatoid papulosis
[LyP]/primary cutaneous large T-cell CD30z lymphoma
[CD30z large CTCL]) and other malignant lymphomas
(mycosis fungoides [MF] or Hodgkin’s disease) is
uncommon (1 – 3). When present, both processes could
develop simultaneously or precede one another by months
to years. Several authors have pointed out that MF cases
associated with a CD30z cutaneous lymphoproliferative
disorder seem to have an indolent clinical evolution and a
more favourable prognosis (4, 5).
The clonal relationship between these lymphoproli-
ferative disorders has been addressed in only a few
cases to date, possibly for technical reasons, such as a
sparse lymphoid infiltrate in skin specimens or a limited
technical sensitivity to detect clonal TCR-c gene
rearrangements (3).
In the present study, we reviewed the clinical,
histopathological and immunophenotypic features in
a series of patients presenting with both MF and LyP
from the Catalonian Cutaneous Lymphoma Network
(Barcelona, Spain). T-cell clonality was evaluated by
PCR and GeneScan analysis (PCR-GSA). The clonal
relationship between MF and LyP lesions in each
individual patient was investigated.
MATERIALS AND METHODS
Patients
Twelve patients with a proven diagnosis of MF associated
with LyP were included in the study.
The diagnosis of each sample specimen was established on
the basis of clinical data, routine histopathological examina-
tion and immunophenotypic expression. The features were
evaluated according to the standard criteria for the diagnosis
of primary cutaneous T-cell lymphoma of the WHO
and EORTC classifications (6, 7). All biopsy samples were
obtained simultaneously for histopathological and molecular
diagnostic purposes.
An individualized clinical protocol was applied to all cases
presenting the association of MF and LyP. The clinical charts
were reviewed by doctors from the different hospitals in Catalonia
(Catalonian Cutaneous Lymphoma Thematic Network).
Methods
Histopathological and immunophenotypic studies. The diagno-
sis of LyP and MF was established on the basis of routine
haematoxylin and eosin (H&E) examination. Immunophenotypic
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analysis was performed by applying a panel of cell surface
lymphoid markers. The studies were performed in all cases
using formalin-fixed paraffin-embedded tissue sections with
en-Vision technique in an automated immunostainer, using
the antibodies CD3, CD8, CD20, CD30 (DAKO, Glostrup,
Denmark), CD4 and CD56 (Novocastra, Newcastle, UK).
Immunohistochemical features were evaluated in both MF
and LyP lesions with special attention being paid to the
CD30 antigen.
Genotypic analysis. The DNA was extracted from paraffin-
embedded biopsies using a QIAamp Tissue Kit (QIAGEN
GmbH, Hilden, Germany). Thus, 200 ng of genomic DNA
were amplified by PCR as described previously by Dippel
et al. (8), but with the following modification: only one
amplification was performed using the oligonucleotide pri-
mers Vc21 – 9 (5’ ACG GCG TCT TC(AT) GTA CTA
TGA C 3’) labelled with FAM, JGT3 (5’ AGT TAC TAT
GAG C(CT) AGT CCC 3’) and JGT1/2 (5’ AAG TGT
TGT TCC ACT GCC AAA 3’).
Fluorescent fragments analysis (GeneScan analysis – GSA).
One ml of the PCR product was mixed with 9 ml of deio-
nized formamide (Applied Biosystems, Foster City, CA,
USA) and 0.5 ml of molecular weight standard (Genescan
400-ROX, Applied Biosystems). The samples were analysed
by an automated fragment ABI 3100 (Genescan system).
The diagnosis of T-cell clonality was established when only
one or two peaks of approximately 200 bp were observed in
all PCRs. Polyclonal cases showed multiple peaks. TCRc
PCR-GSA analysis was performed in triplicate for each skin




The clinical features, the chronological sequence of
both disorders, the different treatments and the clinical
outcome are summarized in Table I.
Twelve patients (mean age 49 years) were included in
the study. The cutaneous lesions were considered
clinically diagnostic of plaque stage MF in eight patients,
whereas in four patients the clinical diagnosis was MF
patch stage (Fig. 1A). Recurrent, self-healing crops of
papules or nodules consistent with LyP were observed in
all the patients (Fig. 1B). One patient (case 2) had been
diagnosed and treated for Hodgkin’s disease 18 years
previously. Another patient (case 6) had developed a
CD30z large CTCL. The onset of both disorders was
simultaneous in four patients, with an overall follow-up
ranging from 4 to 40 years (mean duration of 10 years). In
eight cases, MF lesions preceded the development of LyP
by a period ranging from 2 to 35 years (mean 7 years).
PUVA was the first-line treatment for MF lesions in
nine cases. Two patients with MF patch stage controlled
the disease with topical corticosteroids. In one patient
(case 12), electron beam radiotherapy was chosen for treat-
ment of widespread cutaneous lesions. An improvement of
the disease was achieved in seven cases (two patients with
complete remission). Interferon-a 2a was prescribed in two
patients presenting cutaneous relapses of MF after PUVA
treatment. In case 12, who presented an aggressive long-
standing MF with multiple tumoral lesions and extra-
cutaneous involvement, a chemotherapeutic regime was
necessary. In the majority of cases, LyP lesions were not
treated. In four patients low-dose oral methotrexate was
prescribed because of the number and the evolution of
lesions. At present, most patients still have active lesions of
MF (patch/plaque stage) and/or LyP relapses.
Histopathological and inmmunohistochemical features
Several skin biopsy specimens (from 2 to 10) were
evaluated in each patient. In four cases, histopatholo-
gical examination of MF patches disclosed a discrete
Table I. Clinical characteristics and results of the 12 cases with primary cutaneous T-cell lymphoproliferative (CTCL) dis-
orders mycosis fungoides (MF)/lymphomatoid papulosis (LyP)
Case no. Age/sex CTCL Onset*
Follow-up





1 55/M MF/LyP S 10 Alive PUVA, MTX Non-clonal Non-clonal
2 40/M MF/LyP/HD HD (18 y) S 5 Alive PUVA, IFN,
retinoids, BCNU
Clonal Clonal
3 70/M MF/LyP S (7 y) 7 Alive PUVA, MTX Clonal Clonal
4 69/M MF/LyP MF (6 y) 10 Alive PUVA, MTX Clonal Clonal
5 52/M MF(p)/LyP S 8 Alive PUVA Non-clonal Non-clonal
6 72/F MF/LyP MF (2 y) 4 Alive PUVA, MTX Clonal Clonal
7 46/F MF/LyP MF (5 y) 15 Alive PUVA, BCNU Clonal Clonal
8 40/F MF(p)/LyP MF (3 y) 5 Alive/CR Topical steroids Non-clonal Non-clonal
9 40/F MF(p)/LyP MF (7 y) 12 Alive Topical steroids Clonal Clonal
10 40/F MF(p)/LyP MF (19 y) 21 Alive PUVA Non-clonal Non-clonal
11 41/F MF/LyP MF (10 y) 15 Alive/CR PUVA Non-clonal Non-clonal





HD, Hodgkin’s disease; MF(p), MF patch stage; S, simultaneous; Alive, active lesions of MF/LyP; CR, complete remission (no lesions); RT,
radiotherapy; ChT, chemotherapy; IFN, interferon; MTX, methotrexate; BCNU, carmustine.
*Initial presentation and interval between both disorders.
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band-like inflammatory infiltrate. This involved the
papillary dermis with single cell epidermotropism
showing a histopathological picture consistent with
patch stage MF (Fig. 1C). In these cases, single skin
biopsy specimens may have proved non-diagnostic and
therefore repeated observations and the practice of
repeated biopsies were necessary to establish a definitive
diagnosis. In eight MF biopsies, a classic histopatho-
logical picture of plaque stage MF was observed.
Neoplastic cells expressed a T-helper cell phenotype
CD3z, CD4z, CD82, CD202, CD302 and CD562.
All LyP lesions exhibited a characteristic dense
wedge-shaped mixed inflammatory infiltrate with iso-
lated and clustered large atypical cells (histological type
A LyP). Atypical large cells expressed perinuclear
CD30 antigen within a background of T-helper
(CD4z) lymphocytes (Fig. 1D).
TCRc gene rearrangement and GeneScan analysis
In the PCR-GSA method used, 6 of 12 MF samples
and 7 of 12 LyP samples showed a monoclonal
expansion. A concordance between MF/LyP samples
from the same patient was achieved in 11 of 12 cases
and the amplification fragments showed identical TCRc
rearrangements from MF and LyP lesions in 6 patients
(cases 2, 3, 4, 6, 7 and 9) (Fig. 2). In the remaining 5
patients, we could not demonstrate clonality in either
MF or LyP samples. In one case (case 12), a clonal peak
was detected in the LyP lesion, whereas a pseudoclonal
pattern was detected in the MF lesion (different peaks
were observed after repeated PCR-GSA).
DISCUSSION
It is now generally accepted that primary CD30z
cutaneous lymphoproliferative disorders comprise a
clinical and morphological spectrum, in which a clear
distinction between LyP and lymphoma cannot always
be established (9 – 22). In some patients, LyP precedes,
is associated with, or is followed by primary cutaneous
CD30z lymphoma. Primary cutaneous CD30z dis-
orders are usually characterized by an indolent clinical
course and a good prognosis (12 – 15).
The association of MF and a cutaneous CD30z
lymphoproliferative disorder in the same patient seems
to be an uncommon, but not exceedingly rare
phenomenon (16, 17). In patients with LyP, develop-
ment of MF or other malignant lymphoproliferative
disorders has been reported in between 5 and 15% of
cases (5, 18 – 20). In some instances, LyP and MF seem
Fig. 1. (A) Clinical features of mycosis fungoides patch lesions. (B) Lymphomatoid papulosis. Recurrent necrotic papules. (C) Mycosis
fungoides (patch stage). Single cell epidermotropism by atypical lymphocytes with convoluted nuclei (H&E 6200 ). (D) Lymphomatoid
papulosis. Large atypical cells expressing CD30 antigen (CD30 6400).
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to co-exist as clinically independent disorders, probably
as manifestations of a common clonal origin (21).
The onset of both MF and LyP may be simultaneous
or precede one another by months or years. After
reviewing the clinical features and the evolution of a
series of 15 patients presenting with LyP in association
with MF, Basarab et al. (22) suggested that this group
of patients seems to have a more favourable prognosis.
More recently, Zackheim et al. (23) reported a series of
21 patients with similar results. The majority of MF
lesions observed in our series also corresponded to early
lesions (patches and plaques). In some instances, the
definite diagnosis of MF was established after repeated
biopsies and the evaluation of several skin biopsies.
In our series, all MF cases corresponded to stages IA
(33%) or IB (66%). An indolent clinical course was
observed and no evolution to more advanced stages
after a prolonged follow-up period was noted with the
exception of one patient. This patient developed
tumours and died of advanced CTCL.
An association of CD30z large CTCL and MF has
also been reported. Cases of MF which developed
CD30z large CTCL should be distinguished from MF
showing large cell transformation as they usually have
an aggressive clinical course. This differentiation may
be extremely difficult or even impossible based
exclusively on the histological and immunophenotypical
features (4, 24 – 27).
Since the original description of this association, a
pathogenetic relationship between both disorders has
been postulated (28). The demonstration of a common
clonal origin could theoretically be demonstrated by
means of genotypic analysis. Nevertheless, conventional
PCR-based techniques detect T-cell monoclonality in
only 50% of LyP lesions, and this percentage is even
lower in early MF lesions. The presence of a sparse
lymphoid infiltrate often admixed with a non-neoplastic
reactive lymphoid population may explain these results.
Other possible reasons might be the absence of
rearrangement of the c chain locus in a particular
case, the lack of coverage of all possible V-
J rearrangements of the TCRc locus (i.e. rearrange-
ments of the Vc10 – Vc12 segments were not covered by
our selected set of primers) and specific limitations of
the different technical approaches (29, 30).
Recently, in order to improve the sensitivity of this
analysis, several technical modifications have been
introduced in the studies of T-cell clonality. PCR-
GSA is a new method, which determines dominant T-
cell clones. It seems to be sensitive, accurate, specific
and easier to interpret than standard electrophoresis gel
techniques (8). GSA is a simple quick test with a low
overall cost. This enables an accurate determination of
the size of PCR products and distinguishes between
polyclonal and monoclonal DNA patterns. In our
experience, this technique can detect a T-cell clone at
tumour densities as low as 2%, whereas other authors
have detected densities from 0.5 to 1% (8). The method
seems suitable for analysing skin lesions, where the
lymphoid infiltrate is usually sparse. In addition, it
allows the demonstration of the identity of two
different clonal populations showing an identical peak
size without performing a direct sequencing of the PCR
products (31). Therefore, it is a valuable tool, which
demonstrates a common clonal origin between different
clinical entities. However, taking into account that a
single dominant peak has been observed after PCR-
GSA analysis in some cases of benign inflammatory
cutaneous disorders, repeated determinations to con-
firm a clonal dominance are necessary. Differences in
the size of the dominant PCR products after repeated
determinations may be interpreted as false positive
results (pseudomonoclonality). Using this method, T-
cell clonality could be demonstrated in 58% and 50% of
patients with LyP and early MF lesions, respectively, in
our series. Clonally rearranged TCR genes have been
Fig. 2. TCRc PCR-GSA showing the
same amplification DNA fragment in
both mycosis fungoides (upper panel)
and lymphomatoid papulosis (lower
panel) biopsies in patient 4 (A) and
patient 6 (B), respectively.
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detected in approximately 60% of LyP lesions, depend-
ing on the series and techniques employed. Identical
rearrangements have been demonstrated from both LyP
and associated cutaneous lymphoma lesions (32, 33).
Recently, Steinhoff et al. (34), by using laser beam
microdissection and single cell PCR-TCRc with GSA
analysis, have demonstrated the clonal nature of atypical
CD30z cells in LyP. In 14 skin biopsies of patients
suffering from LyP, CD30z cells showed a clonal TCRc
rearrangement. Moreover, the CD30- cells admixed in the
LyP infiltrate, when individually analysed, displayed
a polyclonal TCRc rearrangement (34). Conversely,
Gellrich et al. (35) failed to detect a monoclonal T-cell
population in CD30z single cells obtained from clonal
cases of LyP. The authors speculated that CD30z large
T-lymphocytes do not represent a uniform tumour cell
population in CD30z lymphoproliferative disorders
encompassing neoplastic cells, bystander T-cells and
occasionally additional clones (35).
However, several genetic studies have pointed out the
presence of a unique clonal expansion in cases of MF
associated with a primary cutaneous CD30z lympho-
proliferative disorder. Basarab et al. (22) demonstrated
that MF and LyP lesions had an identical clone in 3 of
15 patients by Southern blot analysis and PCR single-
strand conformational polymorphisms (PCR-SSCP).
Similar findings have been reported by Wood et al.
(36) in two patients with MF and LyP, employing
PCR-denaturing gradient gel electrophoresis (PCR-
DGGE) and sequencing of the TCRc PCR products.
In two further cases with co-existing MF and LyP,
Chott et al. (37) also reported identical T-cell clones by
PCR-TCRc and b-chain gene rearrangement from both
types of lesions. Assaf et al. (31), employing the PCR-
GSA method, demonstrated a common clonal origin in
one unusual case of indolent T-cell prolymphocytic
leukaemia, which subsequently developed MF, LyP and
CD30z anaplastic lymphoma. This was also confirmed
by the cytogenetic alterations detected by in situ
hybridization in different clones. More recently,
Zackheim et al. (23) studied seven patients and found
an identical clone in lesions of both LyP and MF by
performing PCR heteroduplex analysis (Table II).
The coexistence or subsequent development of
different malignant lymphomas (i.e. Hodgkin’s disease,
T-cell immunoblastic lymphoma) in the same patient
harbouring identical clones has been reported in some
instances (3, 11, 37, 38).
In conclusion, our results show the simplicity of
automated fluorescent fragment analysis by GSA in the
study of T-cell monoclonal populations. We also
illustrate the utility of this technique in demonstration
of an identical T-cell clonal population from different
and coexistent cutaneous lymphoproliferative disorders.
Moreover, this study supports, as has been previously
suggested, that MF and LyP may represent, in some
instances, different clinical manifestations of an iden-
tical T-cell lymphoproliferative clonal expansion.
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